IP Library › Granted Patent US 12,528,841
Granted Patent B2
US 12,528,841 · App. 19/209,113 · Granted Jan 20, 2026

Capsid variants and methods of using the same

Inventors: Ina Chen (Sommerville, MA); Jeff Gerold (Cambridge, MA); Jerrah Holth (Sudbury, MA); Sylvain Lapan (Brookline, MA); Kathy S. Lin (Sommerville, MA); Samuel Wolock (Cambridge, MA)
Assignee: DYNO THERAPEUTICS, INC.
C07K14/015A61K48/0058C12N15/86C12N2750/14122C12N2750/14143C12N2750/14145
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,528,841
App. No.
19/209,113
Granted
Jan 20, 2026
Kind
B2
Abstract

The disclosure is directed in part to variant capsid polypeptides that can be used to deliver payloads.

Claims (33)

1 . A variant adeno-associated virus (AAV) capsid polypeptide having at least 95% sequence identity to SEQ ID NO: 2 and comprising:

(a) a valine at a position corresponding to T593 as compared to SEQ ID NO:

1;

(b) an alanine at a position corresponding to W595 as compared to SEQ ID NO: 1; and

(c) a leucine at a position corresponding to V596 as compared to SEQ ID NO: 1.

2 . The variant AAV capsid polypeptide of claim 1 , which has at least 96% sequence identity to SEQ ID NO: 2.

3 . The variant AAV capsid polypeptide of claim 1 , which has at least 98% sequence identity to SEQ ID NO: 2.

4 . The variant AAV capsid polypeptide of claim 1 , which has at least 99% sequence identity to SEQ ID NO: 2.

5 . The variant AAV capsid polypeptide of claim 1 , which further comprises a serine at a position corresponding to N598 as compared to SEQ ID NO: 1.

6 . The variant AAV capsid polypeptide of claim 1 , which comprises the mutation set of any one of SEQ ID NOs: 39, 51, 67, 70, 90, 100, and 130.

7 . The variant AAV capsid polypeptide of claim 1 , which comprises the amino acid sequence of any one of SEQ ID NOs: 39, 51, 66, 67, 70, 90, 100, and 130.

8 . A recombinant AAV virus particle comprising the variant AAV capsid polypeptide of claim 1 .

9 . The recombinant AAV virus particle of claim 8 , further comprising a nucleic acid molecule comprising a promoter operably linked to a heterologous transgene.

10 . A recombinant AAV virus particle comprising the variant AAV capsid polypeptide of claim 2 .

11 . The recombinant AAV virus particle of claim 10 , further comprising a nucleic acid molecule comprising a promoter operably linked to a heterologous transgene.

12 . A recombinant AAV virus particle comprising the variant AAV capsid polypeptide of claim 3 .

13 . The recombinant AAV virus particle of claim 11 , further comprising a nucleic acid molecule comprising a promoter operably linked to a heterologous transgene.

14 . A recombinant AAV virus particle comprising the variant AAV capsid polypeptide of claim 4 .

15 . The recombinant AAV virus particle of claim 14 , further comprising a nucleic acid molecule comprising a promoter operably linked to a heterologous transgene.

16 . A recombinant AAV virus particle comprising the variant AAV capsid polypeptide of claim 5 .

17 . The recombinant AAV virus particle of claim 16 , further comprising a nucleic acid molecule comprising a promoter operably linked to a heterologous transgene.

18 . An isolated cell comprising the variant AAV capsid polypeptide of claim 1 .

19 . An isolated cell comprising the variant AAV capsid polypeptide of claim 2 .

20 . An isolated cell comprising the variant AAV capsid polypeptide of claim 3 .

21 . An isolated cell comprising the variant AAV capsid polypeptide of claim 4 .

22 . An isolated cell comprising the variant AAV capsid polypeptide of claim 5 .

23 . A recombinant AAV comprising:

(a) an AAV capsid comprising AAV capsid polypeptides, each having at least 95% sequence identity to SEQ ID NO: 2 and comprising:

(i) a valine at a position corresponding to T593 as compared to SEQ ID NO: 1;

(ii) an alanine at a position corresponding to W595 as compared to SEQ ID NO: 1; and

(iii) a leucine at a position corresponding to V596 as compared to SEQ ID NO: 1; and

(b) a minigene having AAV inverted terminal repeats and a transgene comprising a heterologous gene operably linked to regulatory sequences which direct expression of the heterologous gene in a host cell.

24 . The recombinant AAV of claim 23 , wherein the AAV capsid polypeptides each further comprise a serine at a position corresponding to N598 as compared to SEQ ID NO: 1.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2025
From: CHEN, INA; GEROLD, JEFF; HOLTH, JERRAH; LAPAN, SYLVAIN; LIN, KATHY S.; WOLOCK, SAMUEL
To: DYNO THERAPEUTICS, INC.
Reel/Frame 072875/0377 →
Continuity (6)
Continuation 18788938 · Jul 30, 2024
Continuation 18323135 · May 24, 2023
Continuation PCTUS2022077804 · Oct 7, 2022
Provisional Application 63262341 · Oct 10, 2021
Provisional Application 63262330 · Oct 8, 2021
Related Publication 20250320257A1 · Oct 16, 2025
References Cited (180)
US 10786568B2 · Limberis et al. · 2020 [cited by applicant]
US 12116385B2 · Chen et al. · 2024 [cited by applicant]
US 12331081B2 · Chen et al. · 2025 [cited by applicant]
US 12331082B2 · Chen et al. · 2025 [cited by applicant]
US 20150023924A1 · High et al. · 2015 [cited by applicant]
US 20170130245A1 · Kotin et al. · 2017 [cited by applicant]
US 20180066022A1 · Chalberg et al. · 2018 [cited by applicant]
US 20190300904A1 · Gao et al. · 2019 [cited by applicant]
US 20250066428A1 · Chen et al. · 2025 [cited by applicant]
WO WO2005033321A2 · 2005 [cited by applicant]
WO WO2009137006A2 · 2009 [cited by applicant]
WO WO2010093784A2 · 2010 [cited by applicant]
WO WO2010138263A2 · 2010 [cited by applicant]
WO WO2012109570A1 · 2012 [cited by applicant]
WO WO2012145601A2 · 2012 [cited by applicant]
WO WO2013029030A1 · 2013 [cited by applicant]
WO WO2013170078A1 · 2013 [cited by applicant]
WO WO2015038958A1 · 2015 [cited by applicant]
WO WO2015048534A1 · 2015 [cited by applicant]
WO WO2015164757A1 · 2015 [cited by applicant]
WO WO2015191508A1 · 2015 [cited by applicant]
WO WO2017023724A1 · 2017 [cited by applicant]
WO WO2017058892A2 · 2017 [cited by applicant]
WO WO2017100671A1 · 2017 [cited by applicant]
WO WO2017189959A1 · 2017 [cited by applicant]
WO WO2017189963A1 · 2017 [cited by applicant]
WO WO2017189964A2 · 2017 [cited by applicant]
WO WO2017197355A2 · 2017 [cited by applicant]
WO WO2017201258A1 · 2017 [cited by applicant]
WO WO2018022905A2 · 2018 [cited by applicant]
WO WO2018075798A1 · 2018 [cited by applicant]
WO WO2018156654A1 · 2018 [cited by applicant]
WO WO2018174827A1 · 2018 [cited by applicant]
WO WO2018189244A1 · 2018 [cited by applicant]
WO WO2018204786A1 · 2018 [cited by applicant]
WO WO2018204797A1 · 2018 [cited by applicant]
WO WO2018204803A1 · 2018 [cited by applicant]
WO WO2018232055A1 · 2018 [cited by applicant]
WO WO2019006182A1 · 2019 [cited by applicant]
WO WO2019028306A2 · 2019 [cited by applicant]
WO WO2019060454A2 · 2019 [cited by applicant]
WO WO2019076856A1 · 2019 [cited by applicant]
WO WO2019104279A1 · 2019 [cited by applicant]
WO WO2019141765A1 · 2019 [cited by applicant]
WO WO2019158619A1 · 2019 [cited by applicant]
WO WO2019169132A1 · 2019 [cited by applicant]
WO WO2019191701A1 · 2019 [cited by applicant]
WO WO2019195423A1 · 2019 [cited by applicant]
WO WO2019195444A1 · 2019 [cited by applicant]
WO WO2019195449A1 · 2019 [cited by applicant]
WO WO2019207132A1 · 2019 [cited by applicant]
WO WO2019210267A2 · 2019 [cited by applicant]
WO WO2019217911A1 · 2019 [cited by applicant]
WO WO2019221992A1 · 2019 [cited by applicant]
WO WO2019222328A1 · 2019 [cited by applicant]
WO WO2019222329A1 · 2019 [cited by applicant]
WO WO2019222441A1 · 2019 [cited by applicant]
WO WO2019241324A1 · 2019 [cited by applicant]
WO WO2019246480A1 · 2019 [cited by applicant]
WO WO2020014471A1 · 2020 [cited by applicant]
WO WO2020028751A2 · 2020 [cited by applicant]
WO WO2020068990A1 · 2020 [cited by applicant]
WO WO2020069461A1 · 2020 [cited by applicant]
WO WO2020072683A1 · 2020 [cited by applicant]
WO WO2020077165A1 · 2020 [cited by applicant]
WO WO2020142714A1 · 2020 [cited by applicant]
WO WO2020150556A1 · 2020 [cited by applicant]
WO WO2020160337A1 · 2020 [cited by applicant]
WO WO2020168145A1 · 2020 [cited by applicant]
WO WO2020191300A1 · 2020 [cited by applicant]
WO WO2020193799A1 · 2020 [cited by applicant]
WO WO2020198737A1 · 2020 [cited by applicant]
WO WO2020205889A1 · 2020 [cited by applicant]
WO WO2020206189A1 · 2020 [cited by applicant]
WO WO2020210655A1 · 2020 [cited by applicant]
WO WO2020216861A2 · 2020 [cited by applicant]
WO WO2020219988A2 · 2020 [cited by applicant]
WO WO2020223276A1 · 2020 [cited by applicant]
WO WO2020223279A1 · 2020 [cited by applicant]
WO WO2020223280A1 · 2020 [cited by applicant]
WO WO2020227515A1 · 2020 [cited by applicant]
WO WO2021007382A1 · 2021 [cited by applicant]
WO WO2021009684A1 · 2021 [cited by applicant]
WO WO2021016505A1 · 2021 [cited by applicant]
WO WO2021025995A1 · 2021 [cited by applicant]
WO WO2021046155A1 · 2021 [cited by applicant]
WO WO2021050614A2 · 2021 [cited by applicant]
WO WO2021050974A1 · 2021 [cited by applicant]
WO WO2021072197A1 · 2021 [cited by applicant]
WO WO2021073568A1 · 2021 [cited by applicant]
WO WO2021077000A1 · 2021 [cited by applicant]
WO WO2021084133A1 · 2021 [cited by applicant]
WO WO2021102234A1 · 2021 [cited by applicant]
WO WO2021108468A1 · 2021 [cited by applicant]
WO WO2021113767A1 · 2021 [cited by applicant]
WO WO2021142300A2 · 2021 [cited by applicant]
WO WO2021150850A1 · 2021 [cited by applicant]
WO WO2021154923A2 · 2021 [cited by applicant]
WO WO2021155137A1 · 2021 [cited by applicant]
WO WO2021165544A1 · 2021 [cited by applicant]
WO WO2021168509A1 · 2021 [cited by applicant]
WO WO2021179861A1 · 2021 [cited by applicant]
WO WO2021183825A1 · 2021 [cited by applicant]
WO WO2021188993A1 · 2021 [cited by applicant]
WO WO2021202494A1 · 2021 [cited by applicant]
WO WO2021202651A1 · 2021 [cited by applicant]
WO WO2021207077A1 · 2021 [cited by applicant]
WO WO2021216456A2 · 2021 [cited by applicant]
WO WO2021219762A1 · 2021 [cited by applicant]
WO WO2021222148A2 · 2021 [cited by applicant]
WO WO2021222831A2 · 2021 [cited by applicant]
WO WO2021225921A1 · 2021 [cited by applicant]
WO WO2021226008A1 · 2021 [cited by applicant]
WO WO2021226267A2 · 2021 [cited by applicant]
WO WO2021230987A1 · 2021 [cited by applicant]
WO WO2021242909A1 · 2021 [cited by applicant]
WO WO2021243085A2 · 2021 [cited by applicant]
WO WO2021260204A1 · 2021 [cited by applicant]
WO WO2022003211A1 · 2022 [cited by applicant]
WO WO2022020616A1 · 2022 [cited by applicant]
WO WO2022040527A2 · 2022 [cited by applicant]
WO WO2022119871A2 · 2022 [cited by applicant]
WO WO2022126188A1 · 2022 [cited by applicant]
WO WO2022126189A1 · 2022 [cited by applicant]
WO WO2022150634A2 · 2022 [cited by applicant]
WO WO2022155482A1 · 2022 [cited by applicant]
WO WO2022173847A2 · 2022 [cited by applicant]
WO WO2022212928A1 · 2022 [cited by applicant]
WO WO2022221193A1 · 2022 [cited by applicant]
WO WO2022221400A2 · 2022 [cited by applicant]
WO WO2022221404A2 · 2022 [cited by applicant]
WO WO2022221420A2 · 2022 [cited by applicant]
WO WO2022221421A2 · 2022 [cited by applicant]
WO WO2022222869A1 · 2022 [cited by applicant]
WO WO2022226289A2 · 2022 [cited by applicant]
WO WO2022226294A1 · 2022 [cited by applicant]
WO WO2022226301A1 · 2022 [cited by applicant]
WO WO2022226374A1 · 2022 [cited by applicant]
WO WO2022226375A1 · 2022 [cited by applicant]
WO WO2022229702A2 · 2022 [cited by applicant]
WO WO2022229703A2 · 2022 [cited by applicant]
WO WO2022235970A2 · 2022 [cited by applicant]
WO WO2023283962A1 · 2023 [cited by applicant]
WO WO2023284879A1 · 2023 [cited by applicant]
WO WO2023010120A2 · 2023 [cited by applicant]
WO WO2023015297A1 · 2023 [cited by applicant]
WO WO2023023779A1 · 2023 [cited by applicant]
WO WO2023023781A1 · 2023 [cited by applicant]
WO WO2023039476A1 · 2023 [cited by applicant]
WO WO2023039480A2 · 2023 [cited by applicant]
WO WO2023060142A2 · 2023 [cited by applicant]
International Search Report and Written Opinion issued in PCT/US22/77804 dated Feb. 14, 2023 (11 pages). [cited by applicant]
Beharry et al., 2021, “The AAV9 Variant Capsid AAV-F Mediates Widespread Transgene Expression in Nonhuman Primate Spinal Cord After Intrathecal Administration,” Human Gene Therapy 33(1-2): 61-75. [cited by applicant]
Bryant et al., 2021, “Deep diversification of an AAV capsid protein by machine learning,” Nature Biotechnology 39(6): 691-696 https://doi.org/10.1038/s41587-020-00793-4 (13 pages). [cited by applicant]
Büning et al., 2019, “Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors,” Molecular Therapy: Methods & Clinical Development 12: 248-265. [cited by applicant]
Castle et al., 2016, “Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids,” Methods Mol Biol. 1382: 133-149 doi: 10.1007/978-1-4939-3271-9_10 (17 pages). [cited by applicant]
Challis et al., 2019, “Systemic AAV vectors for widespread and targeted gene delivery in rodents,” Nature Protocols 14: 379-414. [cited by applicant]
Chan et al., 2017, “Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems,” Nat Neurosci. 20(8): 1172-1179 doi: 10.1038/nn.4593 (27 pages). [cited by applicant]
Chen et al., 2022, “Engineered AAVs for non-invasive gene delivery to rodent and non-human primate nervous systems,” Neuron 110: 2242-2257 https://doi.org/10.1016/j.neuron.2022.05.003 (40 pages). [cited by applicant]
Choudhury et al., 2016, “In Vivo Selection Yields AAV-B1 Capsid for Central Nervous System and Muscle Gene Therapy,” Molecular Therapy 24(7): 1247-1257. [cited by applicant]
Choudhury et al., 2016, “Widespread Central Nervous System Gene Transfer and Silencing After Systemic Delivery of Novel AAV-AS Vector,” Molecular Therapy 24(4): 726-735. [cited by applicant]
Gao et al., 2004, “Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues,” Journal of Virology 78(12): 6381-6388. [cited by applicant]
Gessler et al., 2019, “Intravenous Infusion of AAV for Widespread Gene Delivery to the Nervous System,” Methods Mol Biol. 1950: 143-163 doi:10.1007/978-1-4939-9139-6_8 (22 pages). [cited by applicant]
Goertsen et al., 2022, “AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset,” Nature Neuroscience 25: 106-115 (26 pages). [cited by applicant]
Hsu et al., 2020, “Structural characterization of a novel human adeno-associated virus capsid with neurotropic properties,” Nature Communications 11: 3279. https://doi.org/10.1038/s41467-020-17047-1 (14 pages). [cited by applicant]
Huang et al., 2019, “Delivering genes across the blood-brain barrier: LY6A, a novel cellular receptor for AAV-PHP.B capsids,” PLoS ONE 14(11): e0225206 https://doi.org/10.1371/journal.pone.0225206 (17 pages). [cited by applicant]
Kondratov et al., 2021, “A comprehensive study of a 29-capsid AAV library in a non-human primate central nervous system,” Molecular Therapy 29(9): 2806-2820. [cited by applicant]
Lin et al., 2020, “AAV9-Retro mediates efficient transduction with axon terminal absorption and blood-brain barrier transportation,” Mol Brain 13: 138 https://doi.org/10.1186/s13041-020-00679-1 (12 pages). [cited by applicant]
Macdonald et al., 2021, “Capsid-Engineering for Central Nervous System-Directed Gene Therapy with Adeno-Associated Virus Vectors,” Human Gene Therapy 32(19-20): 1096-1119 (25 pages). [cited by applicant]
NCBI BLAST Alignment of instant SEQ ID No. 2 and SEQ ID No. 2 of U.S. Appl. No. 18/571,367 (Year: 2024) 10 pages. [cited by applicant]
Nonnenmacher et al., 2021, “Rapid evolution of blood-brain-barrier-penetrating AAV capsids by RNA-driven biopanning,” Molecular Therapy: Methods & Clinical Development 20: 366-378. [cited by applicant]
Ogden et al., 2019, “Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design,” Science 366(6469): 1139-1143 doi:10.1126/science.aaw2900 (9 pages). [cited by applicant]
Kumar et al., 2020, “Multiplexed Cre-dependent selection yields systemic AAVs for targeting distinct brain cell types,” Nat Methods. 17(5): 541-550 doi:10.1038/s41592-020-0799-7 (31 pages). [cited by applicant]
Saraiva et al., 2016, “Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9,” Journal of Control Release 241: 94-109. [cited by applicant]
Song et al., 2022, “Selection of rAAV vectors that cross the human blood-brain barrier and target the central nervous system using a transwell model,” Molecular Therapy: Methods & Clinical Development 27: 73-88. [cited by applicant]
Stanton et al., 2023, “Systemic administration of novel engineered AAV capsids facilitates enhanced transgene expression in the macaque CNS,” Med (NY) 4(1): 31-50 e8 doi:10.1016/j.medj.2022.11.002 (38 pages). [cited by applicant]
Sullivan et al., 2018, “Rationally designed AAV2 and AAVrh8R capsids provide improved transduction in the retina and brain,” Gene Therapy 25: 205-219 https://doi.org/10.1038/s41434-018-0017-8. [cited by applicant]
Tordo et al., 2018, “A novel adeno-associated virus capsid with enhanced neurotropism corrects a lysosomal transmembrane enzyme deficiency,” Brain 141: 2014-2031. [cited by applicant]
Wu et al., 2000, “Mutational Analysis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Construction of AAV2 Vectors with Altered Tropism,” Journal of Virology 74(18): 8635-8647. [cited by applicant]
Yao et al., 2022, “Variants of the adeno-associated virus serotype 9 with enhanced penetration of the blood-brain barrier in rodents and primates,” Nature Biomedical Engineering 6:1257-1271 https://doi.org/10.1038/s4155… [cited by applicant]